Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16771)	4/8/2004 12:10:55 AM
From: Edscharp	Respond to of 17367

Blue, I have to admit I genuinely love the way your emotions pour through your fingers-tips into the keyboard. Raptiva is obviously equivalent to 'rapture' for you. Like DOUBLE WOW..you even began talking in tongues. It's a good thing that sales weren't 7 million. I do believe you would be ascending to Xoma heaven and meeting HIM (Jack Costello). lol.

To: Bluegreen who wrote (16771)	4/8/2004 11:19:06 PM
From: Cacaito	Read Replies (5) \| Respond to of 17367

Strange and interesting piece of information: 80% of subjects treated with Raptiva were biologics naive, no other biologics were used before, many without previous systemic therapy at all (from UBS report). It could mean that patients are mostly responding to their other biologics, and that eventually a group of subjects will start dropping from the other biologics failure, and Raptiva failure will evolve toward the others, eventually a balance of in and outs will happen. And then the combos.